Edition:
India

Aptose Biosciences Inc (APTO.OQ)

APTO.OQ on NASDAQ Stock Exchange Capital Market

3.07USD
19 Jan 2018
Change (% chg)

$0.27 (+9.64%)
Prev Close
$2.80
Open
$2.90
Day's High
$3.09
Day's Low
$2.78
Volume
212,271
Avg. Vol
66,491
52-wk High
$3.09
52-wk Low
$0.78

Chart for

About

Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates... (more)

Overall

Beta: 2.10
Market Cap(Mil.): $33.86
Shares Outstanding(Mil.): 24.17
Dividend: --
Yield (%): --

Financials

BRIEF-FDA Grants Orphan Drug Designation To Aptose Biosciences For CG’806 In Acute Myeloid Leukemia

* FDA GRANTS ORPHAN DRUG DESIGNATION TO APTOSE BIOSCIENCES FOR CG’806 IN ACUTE MYELOID LEUKEMIA Source text for Eikon: Further company coverage:

26 Dec 2017

BRIEF-Aptose Biosciences Inc Q3 loss per share C$0.14

* Aptose reports results for the third quarter ended September 30, 2017

15 Nov 2017

BRIEF-Aptose enters into $15.5 mln common shares purchase agreement with Aspire Capital Fund, Llc

* Aptose enters into $15.5 million common shares purchase agreement with Aspire Capital Fund, Llc

30 Oct 2017

BRIEF-Aptose Biosciences Inc qtrly earnings per share $0.15

* Aptose reports results for the second quarter ended June 30, 2017

09 Aug 2017

Earnings vs. Estimates